AI Article Synopsis
- - Adulthood growth hormone deficiency (GHD) leads to negative changes in body composition, exercise capacity, cardiovascular function, and metabolism, impacting overall quality of life.
- - Long-term treatment with recombinant human GH has been shown to improve fracture risk, lipid metabolism, body composition, and quality of life, with minimal side effects at recommended dosages.
- - Endocrinologists play a crucial role in selecting appropriate candidates for GH therapy, considering their clinical profile, quality of life, and commitment to treatment to ensure effective and safe outcomes.
Article Abstract
The syndrome of growth hormone deficiency (GHD) in adulthood is characterized by adverse changes in body composition, reduced exercise capacity and quality of life, alterations in cardiovascular function as well as in lipid and carbohydrate metabolism. There is enough evidence to support long-term effects of recombinant human GH therapy on fracture risk, lipid metabolism parameters, body composition, and overall quality of life in adults with GHD, with low probability of side effects at currently suggested doses. Nevertheless, the endocrinologist's role in the careful selection of recombinant human GH therapy candidates, based on clinical characteristics, risk factors, degree of quality of life impairment, patient's ability and willingness to adhere to therapy, is of most importance in order to achieve the best efficacy and the greatest therapeutic safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000540046 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!